253.00 +0.30 (0.12%)
After hours: 4:19PM EDT
|Bid||252.32 x 100|
|Ask||252.99 x 300|
|Day's Range||251.17 - 253.55|
|52 Week Range||186.00 - 259.01|
|PE Ratio (TTM)||22.26|
|Earnings Date||Oct 15, 2018 - Oct 19, 2018|
|Forward Dividend & Yield||3.60 (1.44%)|
|1y Target Est||283.70|
The index posted impressive gains this week, boosted by a strong economy and expectations of robust earnings.
As the initial wave of healthcare companies unveil quarterly results, here are three takeaways from earnings calls. 1. Drugmakers are rethinking pricing strategies After Pfizer Inc. earlier this month said it would defer price hikes, Novartis AG said Wednesday, July 18, it will not raise prices for the rest of the year.
A new spin on an old drug could dent demand for Epidiolex, a marijuana-based epilepsy drug. Plus, here's how important Medicare and Medicaid are to UnitedHealth Group's profits.
UnitedHealth delivered an earnings beat, but its shares fell. Johnson & Johnson's stock took a strong jump on earnings, despite recent bad news from a jury.
By all rational measures, United Health (NYSE:UNH) produced a very solid performance for its second quarter fiscal 2018 earnings report. The country’s biggest health-insurance provider exceeded profitability expectations, while meeting the consensus target for revenues. While the “paper stats” were impressive – United Health hit an earnings per share of $3.14, up 3.2% from the $3.04 consensus target – Barron’s Teresa Rivas notes that much of the positive surprise boils down to non-operating factors.
MARKET PULSE A policy being weighed by the Trump administration that could threaten drug price rebates, a widespread feature of the U.S. pharmaceutical system that largely benefits pharmaceutical middlemen, sent shares of those companies down in Thursday trade.
On Wednesday, there were murmurs that an activist investor might get involved in the Cigna (CI)/Express Scripts Holding (ESRX) merger, in which the health insurer plans to buy the pharmacy-benefits manager in a deal worth $54 billion. Leerink's Ana Gupte wades into the world of health-care mega-mergers today, noting that along with Cigna, UnitedHealth Group (UNH) also closed higher on the news yesterday. Gupte argues that while Amazon and Walmart may be able to "enter or deepen" their presence in the drug supply chain, "they would not be able to compete with sophisticated managed care companies such as UnitedHealth, Humana [HUM] and increasingly Anthem [ANTM] on integrated care delivery with coverage absent a substantial MCO acquisition." That said, she writes that Amazon or Walmart could facilitate cross-selling into prescription-drug benefits and increase store traffic by striking a deal with a managed-care organization.
Wall Street's just dinged two of them and rewarded the third -- but Motley Fool analysts take a longer view.
UnitedHealth Group Inc. is among the companies interested in buying Conifer, the health-management unit of Tenet Healthcare Corp., in what could be a deal worth $2 billion or more.
U.S. stock futures pointed lower on Thursday, July 19, and global shares traded mostly to the downside as trade war concerns held down gains. Data from Japan on Thursday illustrated the broader trade war concerns, with exports from the world's third-largest economy to the United States falling 0.9% in June - the first decline in 17 months - even as the country's trade surplus swelled to $5.24 billion thanks to slowing imports of American-made goods. U.S. companies, as well, have begun questioning the impact of Donald Trump's trade policies, according to the Federal Reserve's "Beige Book" survey of regional business sentiment for June.
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after Honeywell reported second quarter adjusted earnings per share and revenue that beat Wall Street Expectations.